M. E. Garza

Viking Systems: Undervalued and Breaking New Ground (OTC:VKNG)

Good posts guys. I take the good feedback and the bad. Thanks for the heads up.

Viking Systems: Undervalued and Breaking New Ground (OTC:VKNG)

Show me the links to the pumping and insider selling. I see no such proof of that. The stock, if anything, is climbing higher.

Buy Shares of Imaging3 in Anticipation of Future FDA Approval

Did you guys read this:

The Company has incurred significant losses from operations, and such losses are expected to continue. The Company's auditors have included a "Going Concern Qualification" in their report for the year ended December 31, 2008. In addition, the Company has limited working capital. The foregoing raises substantial doubt about the Company's ability to continue as a going concern. Management's plans include seeking additional capital and/or debt financing. There is no guarantee that additional capital and/or debt financing will be available when and to the extent required, or that if available, it will be on terms acceptable to the Company. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The "Going Concern Qualification" might make it substantially more difficult to raise capital.

investorshub.advfn.com...

I would encourage all IMGG investors to look closely at VKNG-- which is also in the imaging business, but already has FDA approval AND had 9 Million in revenue -vs- IMGG

Why Has Cel-Sci Quietly Amended Previously Filed Paperwork?

I suggest you read our news at BioMedReports.com- perhaps even sign up for our free newsletter so you can be alerted on other great investing opportunities like CVM- which we started covering when the stock was priced under fifty cents.


On Nov 12 05:29 AM SYED M QUADRI wrote:

> I AM JUST A NEW PLAYER IN THIS CHESS GAME, I LEARNED ABOUT CVM THRU
> YAHOO BULLISH RECOMMENDATIONS (WHO I BLINDLY FOLLOW AND MADE SOME
> GOOD MONEY) AND BOUGHT SOME SHARES TO AVERAGE AROUND 58 CENTS WHICH
> I SOLD FOR $1.02 THEN BOUGHT AGAIN AND SOLD MAKING SOME GOOD PROFITS,
> HOWEVER, I AM STILL HOLDING SOME SHARES AT $1.45 AND WAITING FOR
> GOOD NEWS TO COME FOR MAKING SOME MONEY OUT OF THIS GOOD SHARE.<br/>
>
> KEEP ME POSTED GUYS SO I COULD MAKE SOME MONEY WITH YOUR HELP.<br/>
>
> I AM ALSO VERY FOND OF CTIC AND RAD WHOSE SHARES I AM HOLDING IN
> GOOD QUANTITY BUT LOSING A LOT, HOPE SOMETHING GOOD COMES OUT OF
> THEM TOO?
>
> REGARDS
>

What's in store for CEL-SCI (CVM)

Multikine is a great drug, but I agree that LEAPS shows tremendous potential and is worth getting excited about.

Why Has Cel-Sci Quietly Amended Some Previously Filed Paperwork?

I don't get paid by any company to report news.
As disclosed, I am long CVM. Have been since it was $.29 and plan to be until someone provides me with scientific proof that I shouldn't be.


On Nov 12 09:41 AM [e-mail] wrote:

> Why has Celsci made an amendment?
>
> Why does M.E. Garza continue to put out press releases and articles
> on Celsci? How much are they paying him? How much stock does he have
> to get rid of?

Why Has Cel-Sci Quietly Amended Some Previously Filed Paperwork?

Given the number of shares trading and the number of new investors, I have a feeling you're not alone in thinking that way. ;)


On Nov 12 12:43 PM User 200905 wrote:

> I like Garza's list of facts about CVM. I have read the emotional
> diatribes against CVM written at thestreet.com, and they ignore the
> facts that Garza presents. Investing in CVM stock puts my money at
> risk, but not an unreasonable risk.
>
> Wayne

Why Has Cel-Sci Quietly Amended Some Previously Filed Paperwork?

The product which the FDA has the most interest in is not the VACCINE. It is the LEAPS H1N1 Treatment.

Read the press release:

www.cel-sci.com/press_...


On Nov 12 11:43 AM User 476730 wrote:

> M.E Garza,
> In another post you answered me that CVM is waiting for word on their
> treatment for H1N1- not a vaccine
>
> I'm still confuse with the 2 articles you published at BioMedReports:
>
>
> 1.
> Filing wih the SEC Makes Cel-Sci's Plans Look Even More Enticing
> to Investors
> Written by M.E.Garza
> Tuesday, 25 August 2009 02:27
>
> ... "The latest filing with the SEC confirms, that CEL-SCI has created
> one (and perhaps even several) potential peptide VACCINE/treatments
> against H1N1 swine flu using their L.E.A.P.S.™ technology- a patented,
> T-cell modulation, peptide epitope delivery technology. The platform
> has enabled CEL-SCI to begin pre-clinical formulation, evaluation
> and testing of a new application of its H1N1 VACCINE, which will
> allow the targeting of "mutated" versions of H1N1 swine and other
> influenza viruses. World health officials believe that the influenza
> virus may mutate and evolve between now and the winter flu season.
>
> According to the filing: "In conjunction with the testing, CEL-SCI
> has produced several L.E.A.P.S. flu VACCINES that focus on the conserved,
> non changing epitopes of the different strains of Type A Influenza
> viruses (H1N1,H5N1, H3N1, etc.), including "swine", "avian or bird",
> and "Spanish Influenza", in order to minimize the change of viral
> "escape by mutations" from immune recognition. CEL-SCI's L.E.A.P.S.
> flu VACCINE contains epitopes known to be associated with immune
> protection against influenza in animal models."...
>
> 2.
> Cloak and Dagger Developments at CEL-SCI (Amex:seekingalpha.com/symbo...)
>
> Written by M.E.Garza
> Monday, 14 September 2009 17:00
>
> ... "As I reported in my last article about CEL-SCI Corporation (AMEX:seekingalpha.com/symbo...)
> the company’s latest filing with the SEC confirms that scientists
> there have created one (and perhaps even several) potential peptide
> VACCINES and treatments against the H1N1 swine flu using their L.E.A.P.S.™
> technology- a patented, T-cell modulation, peptide epitope delivery
> technology.
>
> The platform has enabled CEL-SCI to begin pre-clinical evaluation
> and testing of the new applications of its H1N1 VACCINE and treatments,
> which will allow the targeting of "mutated" versions of H1N1 swine
> and other influenza viruses." ...
>
>
> The capital letters at VACCINE are mine.
>
> As far as I understand you mentioned in both articles that CVM has
> been working in both, vaccine and treatment for H1N1. I understand
> they may be waiting for a word on their treatment for H1N1, but why
> do you say they are not in their H1N1 vaccine?
>
> If they have been working in an H1N1 vaccine, wouldn't CVM be affected
> as well, and therefore should be included in your list of companies
> affected by this decision? (I'm referring to your article "CDC Sticking
> with 'Tried and True' Methods for Flu Vaccines" here).
>
> I appreciate you could clarify if CVM has been working in an H1N1
> vaccine besides the treatment you mentioned.
>
> Thanks.

RxNews Recap for Tuesday 11-10-09

Thanks for the heads up. Just added him/her to my list!

Pay close attention to CEL SCI (CVM) in the next two weeks...

Even more in-depth info on this here:

biomedreports.com/arti...

CDC Sticking with 'Tried and True' Methods for Flu Vaccines

Umm.. No. didn't forget to add CVM.
CVM is waiting for word on their treatment for H1N1- not a vaccine.

As far as why Sinovac would be affected by the news... The company has been talking about trying to get into the U.S. market for years, but in the United States, the decision to purchase what types and brands of vaccines is made by CDC upon the
recommendations from the Advisory Committee on Immunization Practices (ACIP), which has 15 committee members
appointed by the Department of Health. In general, the ACIP will recommend 2 - 4 brands of vaccine products from
different manufacturers for each type of infectious diseases. Sinovacs isn't one of them and likely won't be for some time to come given how "conservative" these guys are being. Still, it is a healthy company and one of the ones doing well (as mentioned) by conducting business abroad.

I wouldn't be surprised to see shares break $8 tomorrow and perhaps even $10 in the coming 2-3 months.

CDC will stick with "tried and true" methods for flu vaccine production

OptionsGirl: This is for you: rodman.bluematrix.com/...

CDC will stick with "tried and true" methods for flu vaccine production

OptionsGirl: RIGL had a terrible October (who didn't, huh?), but they seem to be rebounding. Especially after yesterday's trading. Their whole area of development and research represents a significant potential market, so they are worth keeping an eye on.

CDC will stick with "tried and true" methods for flu vaccine production

CVM is not working on a vaccine for H1N1. The news investors are expecting is about their H1N1 "treatment." If you take a closer look at BioSante's pipeline, you'll see what role their vaccine development has there: www.biosantepharma.com... - almost none.

Note also that BOTH those companies traded significantly higher after the news. Not lower.

Cel-Sci: Things Are Just Getting Started

You would be smart to be a long on CVM going forward. That is my own opinion, but one, obviously shared by VFC. Nice take.